Endothelial cells elicit immune-enhancing responses to dengue virus infection

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6408-6415

  Dalrymple, Nadine A ^a   Mackow, Erich R ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; B CELL ACTIVATING FACTOR; BETA INTERFERON; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; RANTES;

ANIMAL CELL; ARTICLE; CAPILLARY PERMEABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DENGUE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INDUCTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

AEDES; ANIMALS; CELL LINE; CYTOKINES; DENGUE; DENGUE VIRUS; ENDOTHELIAL CELLS; FEMALE; HUMANS;

DENGUE VIRUS; DENGUE VIRUS GROUP;

EID: 84864021807     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00213-12     Document Type: Article

References (75)

1. Aird WC. 2004. Endothelium as an organ system. Crit. Care Med. 32: S271-S279.
2. Ariel A, et al. 1997. Induction of T cell adhesion to extracellular matrix or endothelial cell ligands by soluble or matrix-bound interleukin-7. Eur. J. Immunol. 27:2562-2570.
3. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A. 2009. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 83:5408- 5418.
4. Ashour J, et al. 2010. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 8:410-421.
5. Avirutnan P, et al. 2011. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J. Immunol. 187:424-433.
6. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. 1998. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J. Immunol. 161:6338-6346.
7. Avirutnan P, et al. 2006. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193:1078 -1088.
8. Ayalon O, et al. 1998. Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis. Proc. Natl. Acad. Sci. U. S. A. 95: 2435-2440.
9. Azizan A, et al. 2009. Profile of time-dependent VEGF upregulation in human pulmonary endothelial cells, HPMEC-ST1.6R infected with DENV-1, -2, -3, and -4 viruses. Virol. J. 6:49.
10. Azizan A, et al. 2006. Differential proinflammatory and angiogenesisspecific cytokine production in human pulmonary endothelial cells, HPMEC-ST1.6R infected with dengue-2 and dengue-3 virus. J. Virol. Methods 138:211-217.
11. Balsitis SJ, et al. 2009. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am. J. Trop. Med. Hyg. 80:416-424.
12. Balsitis SJ, Harris E. 2010. Animal models of dengue virus infection and disease: applications, insights and frontiers, p 103-115. In Hanley KA, Weaver SC (ed), Frontiers in dengue virus research. Caister Academic Press, Norfolk, United Kingdom.
13. Basu A, Chaturvedi UC. 2008. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol. Med. Microbiol. 53:287-299.
14. Becerra A, et al. 2009. Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo. J. Med. Virol. 81:1403-1411.
15. Bosch I, et al. 2002. Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge. J. Virol. 76:5588 -5597.
16. Camous L, et al. 2011. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117:1340 -1349.
17. Chen YC, Wang SY. 2002. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J. Virol. 76:9877-9887.
18. Cines DB, et al. 1998. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561.
19. Conceicao TM, et al. 2010. Gene expression analysis during dengue virus infection in HepG2 cells reveals virus control of innate immune response. J. Infect. 60:65-75.
20. Dalrymple N, Mackow ER. 2011. Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors. J. Virol. 85:9478 -9485.
21. Diamond MS, et al. 2000. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74:4957- 4966.
22. Durbin AP, et al. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376:429-435.
23. Dvorak HF. 2010. Vascular permeability to plasma, plasma proteins, and cells: an update. Curr. Opin. Hematol. 17:225-229.
24. Fink J, et al. 2007. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl. Trop. Dis. 1:e86.
25. Gomez D, Reich NC. 2003. Stimulation of primary human endothelial cell proliferation by IFN. J. Immunol. 170:5373-5381.
26. Green S, et al. 1999. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J. Infect. Dis. 179:755-762.
27. Gubler DJ. 2006. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found. Symp. 277:3-253.
28. Halstead SB. 2009. Antibodies determine virulence in dengue. Ann. N. Y. Acad. Sci. 1171(Suppl. 1):E48 -E56.
29. Halstead SB. 2007. Dengue. Lancet 370:1644 -1652.
30. Halstead SB. 2008. Pathophysiology, p 265-326. In Halstead SB (ed), Dengue, vol 5. Imperial College Press, London, United Kingdom.
31. Harboe M, Mollnes TE. 2008. The alternative complement pathway revisited. J. Cell Mol. Med. 12:1074 -1084.
32. Ho LJ, et al. 2001. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J. Immunol. 166:1499- 1506.
33. Honda K, et al. 2005. IRF-7 is the master regulator of type-I interferondependent immune responses. Nature 434:772-777.
34. Huang YH, et al. 2000. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. Am. J. Trop. Med. Hyg. 63:71-75.
35. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. 2004. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J. Infect. Dis. 189:1411-1418.
36. Jiang D, et al. 2010. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J. Virol. 84:8332- 8341.
37. Johnson AJ, Roehrig JT. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73:783-786.
38. Johnson AR, Hugli TE, Muller-Eberhard HJ. 1975. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 28:1067-1080.
39. Juffrie M, et al. 2000. Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect. Immun. 68:702-707.
40. Kurane I, et al. 1990. Human immune responses to dengue viruses. Southeast Asian J. Trop. Med. Public Health 21:658-662.
41. Lacroix M. 2008. Persistent use of "false" cell lines. Int. J. Cancer 122:1- 4.
42. Li Y, et al. 2009. ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc. Natl. Acad. Sci. U. S. A. 106:7945-7950.
43. Luscinskas FW, et al. 2000. C-C and C-X-C chemokines trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Ann. N. Y. Acad. Sci. 902:288 -293.
44. Mackay F, Mackay CR. 2002. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol. 23:113-115.
45. Malasit P. 1987. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J. Trop. Med. Public Health 18:316 -320.
46. Mollnes TE, Kirschfink M. 2006. Strategies of therapeutic complement inhibition. Mol. Immunol. 43:107-121.
47. Morgan BP, Harris CL. 2003. Complement therapeutics; history and current progress. Mol. Immunol. 40:159 -170.
48. Munoz-Jordan JL, Bosch I. 2010. Modulation of the antiviral response by dengue virus, p 121-142. In Hanley KA, Weaver SC (ed), Frontiers in dengue virus research. Caister Academic Press, Norfolk, United Kingdom.
49. Munoz-Jordan JL, et al. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79:8004-8013.
50. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. U. S. A. 100:14333-14338.
51. Nilsson G, et al. 1996. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J. Immunol. 157:1693-1698.
52. Pawitan JA. 2011. Potential agents against plasma leakage. ISRN Pharmacol. 2011:975048.
53. Pepini T, Gorbunova EE, Gavrilovskaya IN, Mackow JE, Mackow ER. 2010. Andes virus regulation of cellular microRNAs contributes to hantavirus-induced endothelial cell permeability. J. Virol. 84:11929 -11936.
54. Peyrefitte CN, et al. 2006. Dengue virus infection of human microvascular endothelial cells from different vascular beds promotes both common and specific functional changes. J. Med. Virol. 78:229 -242.
55. Rodriguez-Madoz JR, et al. 2010. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J. Virol. 84:9760 -9774.
56. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A. 2010. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J. Virol. 84:4845- 4850.
57. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559 -568.
58. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208 -10217.
59. Sim RB, Tsiftsoglou SA. 2004. Proteases of the complement system. Biochem. Soc. Trans. 32:21-27.
60. Srikiatkhachorn A. 2009. Plasma leakage in dengue haemorrhagic fever. Thromb. Haemost. 102:1042-1049.
61. St. John AL, et al. 2011. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc. Natl. Acad. Sci. U. S. A. 108:9190 -9195.
62. Stoermer KA, Morrison TE. 2011. Complement and viral pathogenesis. Virology 411:362-373.
63. Talavera D, Castillo AM, Dominguez MC, Gutierrez AE, Meza I. 2004. IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J. Gen. Virol. 85:1801-1813.
64. Tan GK, et al. 2010. A non-mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4:e672.
65. Teijaro JR, et al. 2011. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:980 -991.
66. Thurman JM, Holers VM. 2006. The central role of the alternative complement pathway in human disease. J. Immunol. 176:1305-1310.
67. Thurman JM, et al. 2005. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol. Immunol. 42:87-97.
68. Tuchinda M, Dhorranintra B, Tuchinda P. 1977. Histamine content in 24-hour urine in patients with dengue haemorrhagic fever. Southeast Asian J. Trop. Med. Public Health 8:80-83.
69. Umareddy I, et al. 2008. Dengue virus regulates type I interferon signalling in a strain-dependent manner in human cell lines. J. Gen. Virol. 89: 3052-3062.
70. Undar A, et al. 2002. Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass. Ann. Thorac. Surg. 74:355-362.
71. Valbuena G, Walker DH. 2006. The endothelium as a target for infections. Annu. Rev. Pathol. 1:171-198.
72. Warke RV, et al. 2003. Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J. Virol. 77:11822- 11832.
73. Werfel T, et al. 2000. Activated human T lymphocytes express a functional C3a receptor. J. Immunol. 165:6599-6605.
74. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128 -139.
75. Zhou W. 2012. The new face of anaphylatoxins in immune regulation. Immunobiology 217:225-234.